Hegazy Ragia, Alashhab Mohamed, Amin Madiha
Department of Forensic Medicine and Clinical Toxicology, Benha Faculty of Medicine, Benha University, Benha, Egypt.
J Toxicol. 2011;2011:862153. doi: 10.1155/2011/862153. Epub 2011 May 31.
Background. Arthritis is a common condition that co-exists in the elderly population. This condition leads to frequent administration of comorbid analgesics especially non steroidal anti-inflammatory drugs (NSAIDs). Aim. To study cardiorenal toxicity of celecoxib versus ibuprofen in arthritic patients. Subjects and Methods. Seven hundred ninety-wo arthritic patients were enrolled in the study for 6 months. Three hundred ninety-six patients administered celecoxib 400 mg twice a day; 396 patients administered ibuprofen 300 mg three times a day. Effects measured included investigator-reported hypertension, edema, or congestive heart failure, increases in serum creatinine or reduction in serum creatinine clearance, and changes in serum electrolytes. Results. Celecoxib was associated with significant (P < .05) lower incidence of hypertension and edema in comparison with ibuprofen. Systolic hypertension occurred significantly less (P < .05) with celecoxib compared with ibuprofen. Serum creatinine was significantly increased (P < .05) in patients treated with ibuprofen in comparison with celecoxib. Creatinine clearance was significantly lower (P < .05) in cases treated with ibuprofen in comparison to celecoxib. Nonsignificant changes in serum body electrolytes occurred. Conclusion. The most important finding of this study was the lowering incidence of cardiorenal toxicity of celecoxib in comparison with ibuprofen.
背景。关节炎是一种在老年人群中并存的常见病症。这种病症导致合并使用镇痛药尤其是非甾体抗炎药（NSAIDs）的情况频繁发生。目的。研究塞来昔布与布洛芬对关节炎患者的心肾毒性。对象与方法。792例关节炎患者纳入研究6个月。396例患者每日两次服用塞来昔布400毫克；396例患者每日三次服用布洛芬300毫克。测量的效应包括研究者报告的高血压、水肿或充血性心力衰竭、血清肌酐升高或血清肌酐清除率降低以及血清电解质变化。结果。与布洛芬相比，塞来昔布导致的高血压和水肿发生率显著更低（P < 0.05）。与布洛芬相比，塞来昔布导致的收缩期高血压显著更少（P < 0.05）。与塞来昔布相比，服用布洛芬的患者血清肌酐显著升高（P < 0.05）。与塞来昔布相比，服用布洛芬的病例肌酐清除率显著更低（P < 0.05）。血清电解质无显著变化。结论。本研究最重要的发现是与布洛芬相比，塞来昔布的心肾毒性发生率更低。
